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Abstract
Eliciting neutralizing antibodies capable of inactivating a broad spectrum of HIV-1
strains is a major goal of HIV-1 vaccine design. The challenge is that envelopes
(Envs) of circulating viruses are almost certainly different from any Env used in a
vaccine. A novel immunogen composed of a highly diverse set of gp140 Envs
including subtypes A, B, C, D and F was developed to stimulate a more cross-
neutralizing antibody response. Env heterotrimers composed of up to 54 different
gp140s were produced with the aim of focusing the response to the conserved
regions of Env while reducing the dominance of any individual hypervariable region.
Heterotrimeric gp140 Envs of inter- and intra-subtype combinations were shown to
bind CD4 and a panel of neutralizing monoclonal antibodies with similar affinity to
monovalent UG37 gp140. Macaques immunized with six groups of heterotrimer
mixtures showed slightly more potent neutralizing antibody responses in TZM-BL
tier 1 and A3R5 tier 2 pseudovirus assays than macaques immunized with
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monovalent Env gp140, and exhibited a marginally greater focus on the CD4-
binding site. Carbopol enhanced neutralization when used as an adjuvant instead
of RIBI in combination with UG37 gp140. These data indicate that cross-subtype
heterotrimeric gp140 Envs may elicit some improvement of the neutralizing
antibody response in macaques compared to monovalent gp140 Env.
Introduction
The development of an effective HIV-1 vaccine remains a major global health
priority: recent figures from the World Health Organisation indicate that
approximately 35 million people were living with HIV-1 at the end of 2013.
Whilst the availability of antiretroviral drugs can prolong the lives of HIV-1-
positive individuals in countries where they are readily available, a protective
vaccine would be the most effective way of reducing viral transmission. HIV-1 has
diversified in the human population for many decades, and due to the
extraordinary genetic variety of subtypes now in circulation, a vaccine needs to
induce immunity that targets a wide range of epitopes or targets motifs that are
conserved across most viruses. It is also possible that an effective HIV-1 vaccine
may need to stimulate humoral and cellular immune responses; the recent RV144
trial in Thailand supported the hypothesis that improved protection could be
achieved by combining a T-cell-stimulating vaccine with an antibody stimulating
vaccine [1, 2].
HIV-1 Env is an extensively glycosylated trimer of gp120-gp41 heterodimers
that is critical for binding to the main CD4 receptor and coreceptors; it facilitates
entry into target cells [3] and is the target of neutralizing and broadly neutralizing
antibodies (NAbs and bNABs). To date, various compositions of soluble gp120
and gp140 immunogens have been tested in immunogenicity studies (reviewed in
[4]) and whilst improved responses were observed when using gp140 rather than
gp120 immunogens [5–7], the majority did not elicit Ab responses capable of
potently neutralizing diverse HIV-1 strains. However, passive transfer of bNAbs
can provide protection against vaginal, oral and rectal challenge with SHIV [8–
12], and vaccine-induced NAbs can be similarly protective [13, 14]. Therefore, it is
crucial to understand how bNAbs can be elicited by active immunization.
During chronic infection, potent and cross-reactive NAbs (broadly neutralizing
antibodies; bNAbs) that are capable of neutralizing heterologous viruses of diverse
subtypes develop in of 10–25% HIV-1 infected individuals [15–18].
Characterisation of these responses has shown many of these bNAbs target the
conserved regions near the CD4 binding site (CD4bs) [19] and sites at the base of
the V3 and V1/V2 loops [20], of which some bNAbs are glycan-dependent [21–
23] and some target the membrane-proximal external region (MPER) [24, 25].
The development of bNAbs was shown to correlate with high plasma viremia and
could result from chronic and evolving antigen exposure over a number of years
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that has allowed sufficient somatic hypermutation in the B-cell receptors (BCRs)
and focuses the B-cell response to the conserved neutralisation sites on Env [17].
Some isolated monoclonal bNAbs contain up to 35% somatic hypermutation of
the BCRs [26], suggesting that during the course of infection B-cell responses to
Env adapt to a mutating antigen over time, which may drive their focus to the
most conserved epitope motifs.
A vaccine strategy that aims to mimic the diverse antigenic exposure
experienced during natural infection may generate NAbs of greater breadth and
potency. A polyvalent vaccine, comprising a combination of multiple Env
proteins, was shown to be better in this respect to monovalent Env in both rabbits
and macaques [27–30]. Morner et al. achieved greater focusing of the immune
response on conserved regions of Env by sequential immunization of macaques
with gp120 core protein followed by trimer boosting [31]. Similarly, the
administration of sequential rather than single or mixed patient-derived gp140
Env genes in rabbits showed a marginal improvement in breadth of neutralization
[32]. Sellhorn et al. recently described a novel assembly of gp140 heterotrimers
which had gp140 subunits from two different genetic sources and improved
potency of NAb responses in rabbits as compared to homotrimeric equivalents
[33].
In this study, we created high antigenic diversity with the gp140 immunogens
by forming heterotrimers from a diverse set of HIV-1-infected patient-derived
Env genes from subtypes A, B, C, D and F, and compared their immunogenicity
with homotrimeric UG37 gp140 in rhesus macaques. Inter and intra-subtype
heterotrimers readily assembled. For comparison between the heterotrimers and
homotrimers of gp140 immunogens, RIBI Adjuvant System was used, which is an
oil (squalene)-in-water emulsion. An additional group of macaques was
immunised with the homotrimeric gp140 adjuvanted with carbopol, which is a
polyanionic carbomer gel shown to induce strong specific antibody responses to
HIV-1 Env in mice [34] and rabbits [35, 36]. Carbopol is currently used in animal
vaccinations but its use in humans has not been reported. In the macaque
immunizations reported here, carbopol was well tolerated and resulted in robust
anti-HIV-1 Env responses. An improved targeting to the CD4bs was detected both
with the heterotrimer immunogens and with carbopol as an adjuvant compared
to the monovalent UG37 with RIBI control group. Furthermore, a NAb response
of improved potency against tier 1 and tier 2 HIV-1 pseudoviruses was achieved
with heterotrimer mixes compared to homotrimeric gp140.
Materials and Methods
2.1. Ethics statement
Approval for the work with non-human primates was granted by the Home Office
under the authority of a Project Licence (Licence number PPL 30–2424), granted
under the UK’s Animal (Scientific Procedures) Act and with the endorsement of
the Ethical Review Committee at the University of Oxford.
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2.2. Amplification and sequencing of HIV-1 Env genes
HIV-1 gp140 Env genes were amplified from 84 patient serum samples (collected
by the Centre for AIDS Reagents at the National Institute for Biological Standards
and Control, UK; NIBSC) and sequenced as previously described [37]. Viral RNA
was isolated from patient sera and amplified using Superscript III One-step RT-
PCR with High Fidelity Platinum Taq (Invitrogen) using primers EnvA (fw) and
Env3Rlong (rev) [35]. Where necessary, a further 25-cycle nested PCR reaction
was performed using Advantage 2 Polymerase mix (Clontech) with internal
primers Env_2Flong (fw) and Nef5 (rev) [35]. All primer details can be found in
S1 Table.
PCR products were cloned into the pCR 4-TOPO vector from the TOPO TA
Cloning Kit for Sequencing (Invitrogen) and used to transform One-shot TOP10
chemically competent Escherichia coli. Individual colonies were picked and
shipped to Functional Biosciences, Inc, Madison, WI, USA for sequencing with an
Applied Biosystems 3730xl Genetic Analyzer, as described previously [37].
2.3. Construction of gp140 Env expression plasmids
All Env expression plasmids were made using the pLEXm vector, which is
designed for protein expression in mammalian cells [38]. The human tissue
plasminogen activator leader sequence was used to replace the native HIV-1 gp140
leader, a modification which has been shown to increase gp140 expression [39].
The 39 primer incorporated a XhoI site and a His6 tag sequence followed by a stop
codon. PCR products were digested with EcoRI (New England Biolabs, Beverly,
MA; NEB) and XhoI (NEB), gel purified (Qiagen, Venlo, The Netherlands, and
ligated into the pLEXm plasmid. Ligation reactions were performed at room
temperature (RT) for 1 hr using T4 DNA ligase (NEB) prior to transformation
into DH5 alpha Escherichia coli cells (Invitrogen, Carlsbad, CA). Following DNA
extraction, plasmids were sequence-verified.
Gp140-encoded regions of env were amplified, incorporating the full native
gp120 and gp41 mature protein encoding regions with the furin site replaced with
SEKS and ending with amino-acid position 668, located at the membrane
proximal region of gp41, followed by a His6 tag. All PCR reactions were
performed with KOD DNA Polymerase (Novagen, Madison, WI), according to
the manufacturer’s instructions. Primer details can be found in S1 Table.
2.4. Small-scale gp140 Env expression screen
Env plasmids were screened for protein expression using a 1 ml culture
transfection protocol in high glucose DMEM media (Sigma, St. Louis, MO)
supplemented with 10% fetal calf serum (FCS; Sigma) and Penicillin (100 units/
ml) Streptomycin (10 ng/ml). Two mg of each DNA construct were incubated
with 3.6 mg polyethylelimine (PEI; Sigma) in 150 ml DMEM media for 30 min.
The DNA-PEI mixture was added to 90% confluent cells and the volume made up
to 1 ml with DMEM containing 2% FCS. After 48–72 hr, supernatants were
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analyzed by gel electrophoresis on 4–12% Bis-Tris gels (Invitrogen) and western
blot to detect protein expression levels. Blots were incubated overnight with a
penta-His antibody (Qiagen) followed by 1 hr at RT with an anti-mouse
secondary antibody conjugated with HRP (Invitrogen). A maximum likelihood
phylogeny (TREE-PUZZLE [40]) was constructed from envs that were positive in
the expression screen. Of these, expression plasmids were selected for inclusion in
immunogen mixes based on their gp140 env sequence diversity; envs from
individual subtypes were selected for the different mixes with the exception of Mix
5, which contained envs from both subtypes D and F due to the availability of nine
unique genotypes available for these subtypes. Where possible, envs were selected
from as many different patients as possible, in order to maximise the genetic
diversity represented in each mix (Fig. 1).
2.5. Proof-of-concept of heterotrimeric gp140 production
In order to determine whether heterotrimers that contain three unique gp140
subunits could be produced, a two-stage capture experiment was designed. 293T
cells were co-transfected with three env expression plasmids containing different
C-terminal tags. Gp140 plasmids were cloned where the His6 tag was
replaced by either FLAG: DYKDDDDK, HA: YPYDVPDYA, FLAG-His6:
DYKDDDDKHHHHHH, or HA-His6: YPYDVPDYAHHHHHH tags. 72 hr
following transfection, supernatants were centrifuged at 13,000 rpm for 5 mins,
passed through a 22-mm filter, and adjusted to pH 8 using 1 M Tris-HCl, pH 8
(Sigma). This was passed over a 5 ml Talon metal-affinity Superflow Resin
(Clontech) to specifically bind the His6 tag. Protein was eluted with 250 mM
imidazole (Sigma) and the protein concentrated to 1 ml using 7 ml centrifugation
columns for protein purification with 9,000 kDa molecular weight cut-off (Pierce,
Rockford, IL). Protein was incubated with 20 ml anti-FLAG-tagged magnetic
beads (Sigma) according to the manufacturer’s protocol, washed with 1 M Tris-
HCl pH 8.0 and protein was eluted by competition with the FLAG peptide
(Sigma). The proteins labelled with the different tags were detected by western
blot, as described above; using different antibodies. FLAG expression was detected
using an anti-FLAG M2 mouse monoclonal antibody (Invitrogen) and HA
expression was detected using a mouse anti-HA antibody (AbCam, Cambridge,
UK).
2.6. Expression and purification of gp140 Env immunogens
All gp140 Envs were produced by transient transfection in 293T cells cultured in
multilayer Cell Bind Hyperflasks (Corning, NY each of which was transfected with
2 mg DNA. UG37 DNA was synthesised from the sequence available from
GenBank accession number AAB05027.1. Cells at 80–90% confluency were
transfected with gp140 DNA complexed with PEI at a ratio of 1 mg DNA: 1.8 mg
PEI. DNA-PEI mixtures were incubated for 30 min prior to being added to the
cells in DMEM with 2% FCS. Supernatants were collected after 48 hr and fresh
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media, this time containing 10% FCS, was added to the cells for a further 48 hr at
which point the media were exchanged once again. All supernatants were
centrifuged at 7000 x g for 4 hr to remove cell debris, and passed through a 0.22-
mm filter. After adjusting to pH 8 using 1 M Tris-HCl (Sigma), media were passed
over a Talon Superflow resin (Clontech, Mountain View, CA) column. After
washing with 2 column volumes of 0.015 M Tris Buffered Saline (Sigma), protein
was eluted with 250 mM imidazole. The eluted gp140 was concentrated and
separated by size-exclusion chromatography (SEC) using a Superdex200 26/60
size-exclusion column (GE Healthcare, Pollards Wood, UK). Fractions corre-
sponding to the trimer peak were identified and further purified using GNA-lectin
(Vector Labs, Peterborough, UK) to specifically bind the glycoprotein. An
additional SEC fractionation allowed separation of pure gp140.
2.7. SPR and ELISA Reagents
CD4-IgG2 [41] used in the binding studies was obtained through the NIH AIDS
Reagent Program (source: Progenics Pharmaceuticals, Inc.), Division of AIDS,
NIAID, NIH: Cat#11780. Soluble domains 1–4 CD4 (sCD4) and biotinylated
domains 1–4 CD4 were a gift from Simon Davis [42]. 2G12 [43], 17b [44] and B6
[45] were obtained from the IAVI Neutralizing Antibody Consortium. 5F3 [43]
was purchased from Polymun Scientific (Austria), VRC01 [46] was a gift from Dr
Connors (VRC, NIAID). HGP68, HR10 and HJ16 [19] were a gift from D. Corti
Fig. 1. Genetic diversity of HIV-1 gp140s present in immunogen Mixes 1–6. The phylogeny was constructed from the env nucleotide sequence
alignment using a maximum likelihood model. Edges are coloured according to mix. Due to a high representation of expressing subtype B Envs, the 19
subtype B Envs were partitioned into 2 subtype B groups designated B and B9.
doi:10.1371/journal.pone.0114709.g001
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and A. Lanzavecchia (Institute for Research in Biomedicine, Switzerland).
Biotinylated mAbs were produced using the EZ-Link NHS-LC-Biotin reagent
(Fisher Scientific UK, Loughborough, UK) according to manufacturer’s instruc-
tions.
2.8. ELISA analysis of gp140-CD4 binding
Gp140s were coated on wells of 96-well ELISA plates at 2 mg/ml for 2 hr at 37 C̊.
Plates were then washed three times with PBS containing 0.05% tween-20 (PBST)
and blocked with blocking buffer (2% BSA in PBST) for 1 hr at RT. CD4-IgG2
was titrated onto the plates and incubated for 2 hr at RT followed by another
three washes with PBST and a 1 hr incubation at RT with anti-human-IgG-HRP
secondary antibody (Sigma) at a 1:10,000 dilution in blocking buffer. Binding was
detected with 1-Step Ultra TMB-ELISA Substrate (Thermo Scientific). The
reaction was stopped by addition of 0.5 M H2SO4 and absorption was read at
450 nm. The absorbance of negative controls was subtracted from the data
(,0.1% of maximum binding values) and normalized data were fitted to a
specific one-site binding model (R2 values of fit ranging from 0.93 to 0.99, mean
0.97, median 0.97) in GraphPad Prism v5.0 (GraphPad Software, Inc., San Diego,
CA, USA). 50% effective concentrations (EC50) were defined as the concentration
at which the fitted curve reached an OD of 50% of the maximum binding.
2.9. Surface plasmon resonance analysis of gp140 antigenic site
exposure
Surface plasmon resonance (SPR) analysis was performed on a BIAcore 3000
biosensor (BIAcore, Uppsala, Sweden) at 37 C̊ in HBS-EP buffer (10 mM HEPES,
150 mM NaCl, 0.0005% Tween 20, pH 7.4). 700 resonance units (RUs) of gp140
were coupled to the surface of a CM5 sensor chip using the amine coupling kit
according to manufacturer’s instructions (GE Healthcare UK Ltd, Little Chalfont,
United Kingdom). Kinetic analysis was performed by injecting serial dilutions of
monoclonal antibodies (mAbs) or soluble monomeric CD4 over the chip surface
at 50 ml/min for 5 min followed by a 5 min dissociation phase. For mAbs with
very slow off-rates, an extended dissociation phase of 30 min was used for the
highest two concentrations. The sensor chip surfaces were regenerated between
each cycle by injecting 25 ml 10 mM glycine (pH 2). Double referencing was
performed using a blank control flow cell as well as a buffer injection, and kinetic
rates (kd and ka for dissociation and association rates respectively) were
determined by fitting the data to a 1:1 Langmuir binding model. Dissociation
constants (KDs) were calculated as KD5kd/ka.
2.10. Estimation of gp140 mix complexity by mass spectrometry
The gp140 immunogens were characterized using tandem mass spectrometry
analysis to identify individual gp140 Env peptides within the UG37 and
heterotrimeric gp140s. Proteins were deglycosylated using PNGaseF (NEB) using
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the manufacturer’s instructions, gel electrophoresed and stained with Coomassie
blue. Gel bands corresponding to deglycosylated gp140 (75 kDa) were excised and
an in-gel trypsin digest was performed as described previously [47]. Sample
analysis was performed by nano ultra performance liquid chromatography
tandem mass spectrometry (UPLC-MS/MS) on a Waters Q-Tof Premier mass
spectrometer (Waters) coupled to a nano-UPLC system (NanoAcquity, Waters)
using a reversed phase 75 mm x 250 mm C18, 1.7 mm particle size reversed phase
column as described [48]. Peptides and proteins were identified by Mascot
(v2.3.01 CBRG Cluster) via automated database searching of all MS/MS spectra
against a custom made database including all gp140 protein sequences derived
from the constructs used in this study. The data were analyzed with the following
search parameters: Type of search: MS/MS Ion Search; Enzyme: Trypsin; Fixed
modifications: Carbamidomethyl (C); Variable modifications: Oxidation (M),
Deamidated (NQ); Mass values: Monoisotopic; Protein mass: Unrestricted;
Peptide mass tolerance: ¡0.1 Da (# 13C51); Fragment mass tolerance:
¡0.2 Da; Max missed cleavages: 2; Instrument type: QTOF. Peptide sequences
were compared to a database of the Env proteins used in expression and a score of
the 210 log probability of a particular Env sequence being identified was
calculated. Taking the set of peptides corresponding to a given Env sequence, the
% coverage was derived for each identified Env protein. Due to the similarities
between the different gp140 sequences, MS/MS spectra assignments to sequences
were evaluated manually for all cases in order to provide the information
presented in S2 Table.
2.11. Animals
Fifteen Indian rhesus macaques (Macaca mulatta) previously vaccinated with
HIVconsv antigens aiming to elicit CD8 and CD4 T-cell responses to conserved
parts of the HIV proteome [49] were used in our experiment. No significant Env-
specific T-cell or B-cell responses were detectable at the time of DNA
immunization and no neutralizing antibody titers were detailed at any previous
time point. All the animals in the study were housed and cared for following the
UK’s code of practice for non-human primates. The animals were housed in a
conventional facility in social groups (of 7+) for the duration of the study. The
light cycle is 12 hrs dark and 12 hrs light and the switch from light to dark and
vice versa occurred gradually. The enclosures are 2.2 m high and the allocated
area per animal was between 1.4 to 2.4 m2. The enclosures have a variety of semi-
permanent structures such as perches, swings and ladders at different heights and
windows to the corridor as well as plenty visual barriers.
Other forms of enrichment that are provided routinely include deep bedding
(wood shavings) layered to facilitate foraging, toys (kongs, balls, etc), destructible
items (paper bags, cardboard and wood), foraging devices (puzzles, boxes), frozen
treats, baths and daily interaction with the animals care staff. Daily feeding
includes at least fruit/veg, primate chow (mash form with seeds and raisins) and
two portions forage mix (scattered on bedding). Water was provided ad lib.
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Animals were trained by positive reinforcement to approach the front of the cage
for close inspection and to present and allow topical application of cream on cue.
This facilitated thorough monitoring of the vaccination sites and well as
minimized the need for restraint.
Animals were purposely bred and used in the UK. A health assessment was
carried by the welfare officer and veterinarian at the supplying establishment prior
to shipment and also at the scientific establishment on arrival. Daily checks by
experienced staff were carried out at least twice per day. Monitoring and scoring
systems were used to assess the reaction at vaccination sites. Any reactions where
itchiness/discomfort was suspected were reported straightaway to the welfare
officer add veterinary surgeon and such animals were treated with NSAIDs. There
were no direct adverse effects of the procedure other that the local reactions at the
site of vaccination. All animals acclimatised well to the procedures and were keen
to approach staff and take treats after recovery from blood sampling/vaccinations.
Chemical restraint via use of tranquilizers was utilised to avoid stress/injury (as
manual handling expertise was not available at the time), as detailed below. The
general behaviour and health of the animals remained mostly stable throughout
the study and all the animals were released back to stock at the end of the study
and under the advice of the welfare officer and the veterinary surgeon.
2.12. Immunizations
All animals were male and between two to three years of age at the start of the
immunization schedule and weighed between 5–7 kg. The animals were assigned
into three groups of five animals each. All animals were immunised under
sedation or anaesthesia during the day and in the dedicated animal laboratory
within the housing facility. Intradermal DNA/electroporation was performed
according to the Derma Vax protocol (formerly Cyto Pulse Sciences, now Cellectis
Therapeutics, Paris, France) and subcutaneous protein and ribi/carbopol boosts
were administered in similar locations to the DNA/electroporation prime to act
on the nearby draining lymph nodes. Group 1 received the heterotrimeric gp140
with RIBI (RIBI Adjuvant System; Funakoshi Co. Ltd. Tokyo, Japan) adjuvant,
Group 2 received UG37 gp140 adjuvanted with RIBI adjuvant and Group 3
received UG37 gp140 with carbopol 974P adjuvant. Animals were anaesthetized
only for the purpose of immobilization during vaccination or phlebotomy using
ketamine (10 mg/kg) with optional Isoflurane (5 mg/kg). They were vaccinated
with the following regimens DDPPP where D is 600 mg of plasmid DNA in 600 ml
of saline, and P is 600 mg gp140 protein in 600 ml saline adjuvanted with either an
equal volume of RIBI or 1% (v/v) carbopol. The DNA vaccine was delivered i.d. at
six sites (each arm, each thigh, one upper and one lower back; 100 mg at each site)
with electroporation immediately after injection. A needle array electrode
containing two parallel rows of four 2 mm pins (1.564 mm gaps) was used and
was performed using the Derma Vax DNA Vaccine Skin Delivery System. Protein
immunizations were also performed at these six sites (100 mg gp140 protein per
site). For the heterotrimer gp140 mixes, the different mixes were rotated between
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the six injection sites to enhance exposure of the local draining lymph nodes to a
wider range of Env gp140 heterotrimer diversity. Macaque blood was drawn from
superficial leg veins at the time of each immunization and two weeks after each
protein boost. Blood samples were kept at room temperature and were processed
within 2 hours of sampling. Serum was separated by centrifugation at 2500 rpm
for 10 min in vacutainers (BD Biosciences, San Jose, CA) and stored at 280 C̊
until required. All animal procedures and care strictly conformed to UK Home
Office Guidelines. Experiments were conducted according to the National Center
for the Replacement, Refinement, and Reduction of Animals in Research,
according to EU Directive 2010/63/EU.
2.13. Analysis of gp140-specific antibodies in macaque sera
End-point titers were determined as previously described [50]. Briefly, antigens
(1 mg/ml in 0.1 M NaHCO3, pH 8.5) were used to coat wells of ELISA plates
(Greiner Bio-One) at 4 C̊ overnight. Wells were blocked with 2% milk in PBST
and incubated with serial dilutions of serum in sample buffer (1% BSA in PBST)
for 1 h at RT followed by labelling with goat anti-human IgG-HRP (1:10,000 in
sample buffer; Jackson ImmunoResearch) and developing with 1-Step UltraTMB-
ELISA Substrate (Thermo Scientific). The reaction was stopped by addition of 0.5
M H2SO4 and absorption was read at 450 nm. Data were fitted to a sigmoidal
dose-response curve in GraphPad Prism v5.0 and end-point titers were defined as
the serum dilution at which the fitted curve reached a value of 0.01 which was
more than two standard deviations above the background of no serum control
wells.
2.14. Viral neutralization assays
Neutralizing antibody activity was measured in 96-well culture plates by using
Tat-regulated luciferase (Luc) reporter gene expression to quantify reductions in
virus infection in either TZM-bl or A3R5 cells. Assays in TZM-bl cells were
performed with Env-pseudotyped viruses as described previously [51]. TZM-bl is
a genetically engineered HeLa cell line (also known as JC53-BL) that expresses the
CD4 receptor and the CCR5 and CXCR4 coreceptors [52] and contains Tat-
regulated reporter genes for firefly Luc and Escherichia coli b-galactosidase under
regulatory control of an HIV-1 long terminal repeat sequence [53]. The cells were
obtained from the NIH AIDS Research and Reference Reagent Program, as
contributed by John Kappes and Xiaoyun Wu. Neutralization assays were
performed with heat-inactivated (56 C̊, 1 hr) serum samples, tested at 3-fold
dilutions ranging from 1:20 to 1:43,740. Diluted samples were pre-incubated with
virus (,150,000 relative light unit equivalents) for 1 hr at 37 C̊ before addition of
cells. Following 48 hr incubation, cells were lysed and Luc activity determined
using a microtiter plate luminometer and BriteLite Plus Reagent (Perkin Elmer).
Neutralization titer (IT50) is the sample dilution at which relative luminescence
units (RLU) are reduced by 50%, compared to RLU in virus control wells after
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subtraction of background RLU in cell control wells. A3R5 (A3.01/R5.6) is a
derivative of the CEM human lymphoblastoid cell line that naturally expresses
CD4 and CXCR4 [54] and was engineered to express CCR5 [55]. The A3R5 assay
was performed with Env.IMC.LucR viruses [56] because multiple rounds of
replication are needed to achieve an adequate infection signal in this assay [55]. As
with the TZM-bl assay, diluted samples were incubated with virus (,50,000 RLU
equivalents) for 1 hr at 37 C̊ prior to adding cells. After incubating for four days, a
defined portion of the cell suspension was transferred to 96-well white solid plates
(Costar, Washington, DC) for measurement of luminescence using the ViviRen
Live Cell Substrate as described by the supplier (Promega, Madison, WI). For each
animal, pre- and post-immune serum samples were assayed side-by-side. Post-
immune samples were scored positive for neutralizing antibody activity if the
neutralization titer was >3x that of the pre-immune sample.
2.15. Competition ELISAs
For cross-competition ELISA, UG37 gp140 was coated onto 96-well plates,
washed and blocked as in a standard ELISA. Titration series of macaque sera were
added to the wells, directly followed by biotinylated mAbs at their respective 50%
binding concentration and the plates were briefly shaken. After 2 hr incubation at
RT, plates were washed three times and streptavidin-biotinylated HRP (GE
Healthcare) at 1:1000 in blocking buffer was used for detection as described
previously. Data were background-subtracted and normalized to control wells not
containing competing sera. 50% inhibition titers (IT50) were determined by
fitting a three-parameter dose response curve to the data in GraphPad Prism v5.0
under restriction of the ‘Top’ value to 1.0. IT50 values were defined as the serum
dilution at which the values of the fitted curve were reduced by 50%.
2.16. Statistical analysis
All statistical analyses were conducted using Graph Pad Prism v5.0. Where data
conformed to a Gaussian distribution (as tested by the D9Agostino & Pearson
omnibus normality test) and variances did not differ (as tested by Bartlett’s test
for equal variances), parametric ANOVAs were selected; where data did not fit a
Gaussian distribution, non-parametric tests were selected. The gp140 ELISA data
were analyzed using ANOVAs with Bonferroni post hoc tests on log-transformed
data. Comparisons between different time-points for each group in the UG37
ELISA were made using one-way ANOVAs; comparisons between groups in the
protein mix ELISAs were made using two-way ANOVAs. For the neutralization
data, a Kruskal-Wallis test was performed for each pseudovirus with Dunn’s post-
hoc tests to compare each of Group 1 and Group 3 with the control Group 2.
Comparisons of composite neutralization data between Groups 1 and 3 with
Group 2 were made using non-parametric Mann Whitney tests. For the
competition ELISAs a one-way ANOVA was performed for each Ab on log-
transformed data with Dunnett’s post-hoc tests to compare Group 1 and Group 3
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with the control Group 2. All tests were two-sided and the post-hoc analyses
incorporated corrections for multiple tests. Significance was determined at
*p,0.05, **p,0.01, ***p,0.001, and ****p,0.0001.
Results
3.1. Isolation, screening and selection of patient-derived env
genes
Sera from 84 HIV-1-positive individuals collected by the Centre for AIDS
Reagents at the NIBSC were included in an initial screen of env sequences. These
included individuals from diverse geographic regions who were infected with
HIV-1 of subtypes A, B, C, D, F and CRF_AE, and who displayed varying levels of
bNAbs in their sera (data not published). Viral RNA was extracted from patient
sera and env genes amplified and sequenced. A total of 661 sequences were
obtained from 58 individuals with an average of 11 sequences per patient (range
2–35). From these, 224 env genes were cloned into the pLEXm protein expression
vector and screened for their ability to express gp140 following transient
transfection of 293 T cells. A total of 54 env clones were selected for inclusion in
the immunization study based on their protein expression ability and on their
phylogenetic distribution (Fig. 1). These formed five groups of envs with the
following compositions: Mix 1 comprised 15 subtype A; Mix 2 comprised 9
subtype B; Mix 3 comprised 10 subtype B (herein referred to as subtype B9 to
differentiate from Mix 2); Mix 4 comprised 11 subtype C; Mix 5 comprised 9
subtype D and F.
3.2. Production of heterotrimers following co-transfection of
multiple Env expression constructs
A proof-of-concept experiment was set up to identify heterotrimer formation
both within and between HIV-1 subtypes. Six cultures of 293 T cells were each
transiently transfected with three env expression constructs containing different
N-terminal tags: one His6, one FLAG and one HA, and each encoding a different
Env. Flasks 1–3 were transfected with three env genes of the same HIV-1 subtype:
A, B, or C, respectively. Flasks 4–6 were transfected with three env genes of
different subtypes (Flask 4: subtypes A, B and C; Flask 5: subtypes A, D and F;
Flask 6: subtypes B, C and F). After 48 hr, supernatants were collected and
screened for expression of gp140 by western blot using antibodies against His6,
FLAG and HA (Fig. 2A). In all six combinations, the three tags were detected,
demonstrating the co-expression of multiple gp140s in the transfection super-
natants, although the ratios of the tags did vary across samples.
To prove true heterotrimers had formed and all three tags were present within
individual trimers, a two-stage capture experiment was conducted. Supernatant
was first passed over a Talon (Clontech) cobalt chloride metal-affinity column to
specifically bind His6-tagged protein, capturing gp140s with at least one His6-
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tagged monomer. The eluates from this column were then incubated with
magnetic beads coated with anti-FLAG antibodies, thus capturing trimers that
had both the His6 and FLAG tags. Eluted proteins were analyzed by western
blotting with an HA antibody to detect the presence of the third tag (Fig. 2B). The
HA tag was detected in all six supernatants following both His6 and FLAG
capture, demonstrating the ability of heterotrimers to form, both within and
between HIV-1 subtypes. However, levels were low, indicating that these
heterotrimers may be quite rare. Controls were included to ensure the specificity
of antibody detection by western blot and the specificity of binding to both the
Talon cobalt chloride resin and the anti-FLAG-tagged magnetic beads (S1 Figure).
3.3. Purification and antigenic characterisation of gp140 protein
immunogens
The principal hypothesis of this study is that the large antigenic diversity achieved
through the immunization with polyvalent heterotrimeric gp140 mixtures may
result in NAb responses of greater breadth and potency as compared to a single
Fig. 2. Non-reducing SDS-PAGE and western blot analysis of gp140 expression following co-transfection of multiple env plasmids. Six flasks were
transiently transfected with three different gp140 env plasmids. 1:3x subtype A, 2:3x subtype B, 3:3xsubtype C, 4: subtypes A, B and C, 5: subtypes A, D
and F, 6: subtypes B, C and F. (A) Detection of gp140 proteins in supernatant with anti-His6, anti-FLAG and anti-HA antibodies. All three tags were detected
for each of the six env combinations. (B) Detection of HA-tagged gp140 in transfection supernatant, after His6-capture with Co
2+ beads, and after FLAG-
capture with anti-FLAG-tagged magnetic beads. The HA tag was detectable at all stages in all six transfections.
doi:10.1371/journal.pone.0114709.g002
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homotrimeric gp140. This would be either from focusing on epitopes conserved
between Envs or an expansion of multiple B-cell specificities to the spectrum of
epitopes presented by immunization. Having shown the feasibility of production
of heterotrimers by co-transfection of multiple gp140 env expression plasmids, a
series of env plasmid combinations was designed for a macaque immunization
study. A total of 54 env plasmids with good expression levels and of diverse genetic
representation were selected by phylogenetic analysis for expression of six
immunogen mixtures (Fig. 3A; Mixes 1–6).
Following large-scale transfection the gp140 trimers were purified to .95%
purity for immunization studies. First, the His6-tagged gp140 was captured by a
Talon cobalt chloride metal-affinity column and the eluted proteins were further
purified by SEC to resolve the different oligomeric forms: aggregates, trimers,
dimers and monomers. Fractions corresponding to the trimer peak were further
purified using GNA-lectin affinity capture, which binds specifically gp140, and
this was followed by an additional SEC step which resulted in a well resolved
single peak with a molecular weight corresponding to the trimer. The purity of the
gp140 immunogens was assessed by SDS-PAGE under reducing conditions; all
proteins separated into monomeric gp140s in the presence of DTT (Fig. 3B).
The accessibility of the CD4bs on the gp140 trimers was verified by ELISA using
a soluble tetrameric human IgG2-CD4 fusion protein. All seven trimer
preparations bound with high affinity to soluble IgG2-CD4 with ELISA-derived
EC50s ranging from 0.18 nM for UG37 to 4.28 nM for Mix 2 (Fig. 3C). Binding
properties of UG37 and Mix 6, the latter containing all 54 Env proteins, were
further analyzed by SPR (Fig. 3D). This method confirmed binding of soluble
monomeric CD4 (sCD4) to both antigens and in addition showed binding to a
panel of mAbs targeting the CD4bs (VRC01 and 15e), the core epitope (HJ16), the
V3 loop (HR10), gp41 (5F3), and the glycan shield (2G12). The mAbs tested
bound with a broad spectrum of SPR-derived KDs ranging from 0.01 nM to
40 nM for mAbs 5F3 and 15e, respectively.
To verify the diversity of the gp140 mixtures expressed from cells, we addressed
expression of individual Env proteins using tandem mass spectrometry (MS). S2
Table shows all gp140 sequences identified by MS as well as the assignment of
unique peptide sequences that relate to each gp140 genotype. The compilation of
peptide ‘signature’ sequences unique to each expected Env genotype in the co-
transfected DNA plasmid mixtures confirmed that between 30% (Mix 3) and 71%
(Mix 1) of Env genotypes could be positively identified. This clearly indicated that
a large proportion of the gp140 genotypes were co-expressed and purified in the
final protein immunogens, thus confirming the production of novel gp140
immunogens containing substantial protein diversity. It is possible that for
peptides that were not detected, the fragments could have had reduced ionization
efficiency or confounding masses, or were produced at lower levels such that they
escaped MS based detection.
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3.4. Immunization of macaques with gp140 proteins
Fifteen male rhesus macaques were immunized with the gp140 trimers (Fig. 4), in
three groups of five macaques to compare (i) heterotrimeric gp140 mixtures with
homotrimeric UG37 gp140 (Group 1 vs. Group 2), and (ii) RIBI with carbopol
974P (Group 2 vs. Group 3). Group 1 received the polyvalent gp140 heterotrimer
mixtures adjuvanted with RIBI (Heterotrimer RIBI). Group 2 received
homotrimeric UG37 gp140 adjuvanted with RIBI (UG37 RIBI). Group 3
macaques received UG37 gp140 adjuvanted with carbopol (UG37 carbopol).
The immunization schedule consisted of two DNA gp140 primes which had
been shown to assist in the development of more robust neutralizing responses
when followed by a protein boost [57], spaced by two months and followed by a
four month resting period and then three protein boosts at two or three month
intervals (Fig. 4A). Blood samples were collected at each immunization and two
weeks after each protein boost. Each boost consisted of six separate injections at
different anatomical sites. For Group 1, each of the six injections consisted of one
Fig. 3. SDS-PAGE and antigenic verification of gp140 protein immunogens. (A) Components of immunogens; protein immunogens were derived by co-
transfection of multiple gp140 env plasmids. Mix 1: subtype A; Mix 2: subtype B; Mix 3: subtype B9; Mix 4: subtype C; Mix 5: subtype D and F; Mix 6: all envs
from Mixes 1 to 5. (B) SDS-PAGE analysis of gp140 immunogens. Proteins were separated under reducing conditions and stained with Coomassie Blue. M:
Protein marker, U: UG37, 1–6: Mixes 1–6. Bands correspond to gp140 monomers. (C) ELISA analysis of tetrameric CD4-IgG2 binding to all gp140
immunogens. Values shown are the concentrations of CD4-IgG2 required to reach 50% of the maximum signal. (D) Surface plasmon resonance (SPR)
analysis of a panel of monoclonal antibodies and monomeric soluble CD4 binding to UG37 and heterotrimer Mix 6. Epitopes targeted are specified in
parentheses. Dissociation constants are derived from a kinetic analysis of the binding curves.
doi:10.1371/journal.pone.0114709.g003
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of the six different gp140 mixes (Fig. 4B); these were rotated between the six sites
so that local draining lymph nodes would encounter gp140 proteins of different
HIV-1 subtypes throughout the study. Overall, carbopol was better tolerated than
RIBI in the macaques, with the latter adjuvant producing some local swelling and
occasional ulceration.
3.5. All macaques generated gp140-specific binding antibodies
following gp140 trimer immunization
Levels of gp140-specific binding antibodies in sera from all macaques were
analyzed by end-point ELISA using plates coated with UG37 gp140 (Fig. 5A).
Macaques in all groups generated robust gp140-specific antibody responses
detectable two weeks after the first protein trimer immunization which were
boosted further following the second protein immunization, however the third
boost did not show a significant increase in gp140-binding titers. In all three
groups, antibody binding titers two weeks after each protein immunization were
significantly greater than titers at the time of immunization (p,0.0001). Data for
individual macaques at each time-point are given in S3 Table.
Between protein immunizations, a significant decline (up to 10-fold from peak)
in titers occurred in all macaques (Fig. 5A). Persisting titers between adminis-
trations were higher at the earlier time-points in Groups 2 and 3 than in the
Group 1 macaques, but the titers post final boost were equivalent in all groups
(Fig. 5A).
Fig. 4. Immunization schedule. (A) Timeline of DNA and protein immunizations. Macaques were each given two DNA priming injections spaced by two
months followed by a four-month interval and then three gp140 protein boosts, spaced by two-month intervals. Blood was collected at the time of each
protein boost and two weeks after each boost (*). A final bleed was collected eight weeks after the final boost. (B) Each immunization consisted of six
separate injections at different sites on the macaques. In the heterotrimer group the six different immunogens were rotated around these sites so that any
local draining lymph nodes experienced different immunogens after each injection. Details given here indicate which Mix immunogen was administered at
each site (1–6) and the contents of those mixes; ‘15 6 subtype A’ indicates that Mix 1 contains heterotrimers generated from 15 subtype A Envs.
doi:10.1371/journal.pone.0114709.g004
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Peak gp140 Ab titers two weeks after each trimer administration were slightly
higher in Groups 2 and 3 than in the Group 1 macaques (Fig. 5A), though the
differences did not reach statistical significance at any time-point (p.0.05). These
differences could reflect the use of UG37 gp140 as the plating antigen for the
ELISA, as Group 1 macaques did not receive this trimer in their immunizations,
and ELISA titers for this group comprise UG37 gp140 cross-binding titers.
To determine whether gp140-binding Ab titers were actually lower in Group 1
macaques than in those macaques that had received UG37 immunogens (Groups
2 and 3) or whether this was due to the plating antigen being UG37, serum
samples from Groups 1 and 2 were also tested for binding against the individual
protein mixtures (Fig. 5B). Two weeks after the third trimer boost, peak titers
were significantly higher in Group 1 macaques than in Group 2 macaques for all
mixes (Mix 1: p,0.05; Mix 2: p,0.001; Mix 3: p,0.0001; Mix 4: p,0.01; Mix 5:
Fig. 5. ELISA analysis of gp140-specific antibody levels in macaque sera. (A) Log10 end-point ELISA
titers assayed against UG37 gp140 at the time of each trimer protein boost, two weeks after each protein
boost, and at the final bleed. Titers are represented as serum dilution factors (1/x). Group mean titers are
plotted with error bars to indicate the standard error of the mean. (B) Mean log10 end-point titers against UG37
and individual protein mixes (Mixes 1–6) for Group 1 (Heterotrimer, Ribi) and Group 2 (UG37, Ribi) macaques
two weeks after the third protein boost. Error bars show standard error of the mean. For both, end-point titers
were defined as the serum dilution at which the fitted sigmoidal dose-response curve reached an OD450 of
0.01.
doi:10.1371/journal.pone.0114709.g005
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p,0.0001; Mix 6 p,0.001). Interestingly, the difference was least marked for Mix
1, perhaps due to the immunogen UG37 being of the same HIV-1 subtype as the
plating antigen in that case. For both groups of macaques, the binding titers were
variable, but present against all mixes.
3.6. Breadth and potency of neutralization was slightly improved
in macaques that received heterotrimers or UG37 with carbopol
compared to UG37 RIBI
To examine the breadth of neutralization a standardized panel of tier 1
pseudoviruses in a TZM-bl assay was used to assess sera taken two weeks after the
third protein boost. Neutralization of six tier 1 pseudoviruses of subtypes B, C and
CRF01_AE was observed; results are shown as reciprocal serum dilutions able to
achieve 50% neutralization of a given pseudovirus (Table 1). Group 1 showed
neutralizing titers against six pseudoviruses whereas groups 2 and 3 showed
neutralization of five pseudoviruses.
For each pseudovirus, the median neutralization titer was calculated. Thus,
neutralization of MN.3 (subtype B), MW965.26 (subtype C), and TH023.6
(CRF01_AE) was achieved in all macaques of all groups, an unsurprising result
given their relative sensitivity to neutralization. Both the Group 1 (20 data points
greater than median) and Group 3 (15 data points greater than median) showed
better overall neutralization than the Group 2 macaques (5 data points greater
than median). Additionally, titers were significantly greater, indicating a greater
potency in Group 1 compared to Group 2 for SF162 (p,0.01), BX08 (p,0.05)
and MN.3 (p,0.05). None of the differences between Group 2 and 3 macaques
reached statistical significance. A composite analysis of the neutralization data
from all pseudoviruses confirmed statistical significance for the marginally greater
titers of Group 1 (p50.0473), but not Group 3 as compared to Group 2 control
macaques (S2 Figure).
Neutralization of tier 2 pseudoviruses on the same serum panel was detected in
the more sensitive A3R5, but not in the TZM-bl neutralization assay (Table 2).
Again, all macaques were able to neutralize some IMC.LucR viruses from the
panel, although for many, the titers were only slightly above the baseline of the
assay. Both Groups 1 and 3 showed greater breadth of neutralization than the
Group 2 macaques. In this assay, titers were significantly greater in Group 1 as
compared to the Group 2 controls for CAP45 (subtype C; p,0.05) and RHPA
(subtype B; p,0.05), whilst titers were significantly greater in Group 3 as
compared to the Group 2 controls for CAP45 (subtype C; p,0.01), Ce1176
(subtype C; p,0.05) and Du151 (subtype C; p,0.05). Analysis of composite
neutralization titers showed greater overall potency in Group 3 macaques as
compared to Group 2 (p50.0138), with Group 1 not reaching statistical
significance. Together, these results indicate that the Group 1 and 3 immunogens
generate slightly greater breadth and potency of neutralization than the Group 2
control immunogen.
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All neutralization assays were performed on sera from two weeks after the third
protein boost where the gp140-ELISA titers were high (Fig. 5A). For four
macaques (macaques 2, 5, 9 and 14; Tables 1 and 2), neutralization titers were also
determined against the Tier-1 pseudotyped viruses MN.3 and MW965.26 for all
time-points using the TZM-bl assay. As expected, titers fluctuated over the course
of the study, with peaks in neutralization titers correlating with the peaks and
troughs in ELISA titers during the protein boosts (S3 Figure).
3.7. Antibodies target multiple regions of Env
Cross-competition ELISA was used where antibodies in the sera competed for
gp140 binding with sCD4 and a panel of mAbs to map the binding specificities of
the serum antibodies. This assay was performed on both pre-immune serum and
serum taken two weeks after the third (final) protein boost. None of the pre-
immune sera competed with any of the probes in this assay (data not shown). In
contrast, sera collected two weeks after the final immunization showed
considerable competition with sCD4 and the CD4bs antibody B6. The former was
significantly higher in both the Group 1 and 3 macaques compared to the Group 2
control macaques (p,0.01, Fig. 6). In all macaques, competition was detected
Table 1. ID50 tier-1 pseudotyped virus neutralization titers in the TZM-bl assay.
Env-pseudotyped viruses
Immunogen Macaque SF162 BX08 92BR025.9 MN.3 MW965.26 TH023.6
Heterotrimer 1 845# 25 21 1453 949 428
RIBI 2 150 20 29 680 2004 1201
(Group 1) 3 3880 37 29 5417 6016 269
4 4026 50 20 7471 5792 3275
5 223 25 64 844 9888 2558
Group mean 1825 31 33 3173 4930 1546
6 24 20 57 191 1795 274
UG37 7 31 20 20 120 3140 600
RIBI 8 50 20 41 464 1259 1137
(Group 2) 9 56 20 36 225 2498 1534
10 76 20 31 318 2358 337
Group mean 48 20 37 264 2210 776
11 20 20 25 25 1997 2991
UG37 12 891 20 89 477 27264 9869
Carbopol 13 68 20 66 361 2164 1862
(Group 3) 14 153 20 61 691 5543 1728
15 124 20 42 160 3759 759
Group mean 251 20 57 343 8146 3442
Median$ 124 20 36 464 2498 1201
#Numbers given are the sample dilutions at which relative luminescence units (RLU) were reduced by 50% compared to RLU in virus control wells after
subtraction of background RLU in cell control wells. All samples were taken two weeks after the third protein boost.
$Values above the median titer for each pseudovirus are shown in bold.
doi:10.1371/journal.pone.0114709.t001
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Table 2. ID50 tier-2 pseudotyped virus neutralization titers in the A3R5 assay.
Env-pseudotyped viruses
Immunogen Macaque CAP45 Ce1086 Du151.2 Ce1176_A3 C1080.c03 R2184.c04 SC22.3C2 RHPA
1 73# 64 48 44 161 36 218 317
Heterotrimer 2 66 51 52 37 596 53 520 354
RIBI 3 95 104 56 43 418 64 312 373
(Group 1) 4 62 35 43 25 522 40 334 306
5 145 164 75 46 854 90 1624 347
Group mean 88 84 55 39 511 57 602 339
6 20 95 54 39 206 35 470 145
UG37 7 20 52 47 22 204 26 149 61
RIBI 8 20 94 61 33 554 58 356 217
(Group 2) 9 20 72 40 25 991 43 386 147
10 20 75 71 37 332 57 663 275
Group mean 20 78 55 31 457 44 405 169
11 72 69 62 52 1781 44 287 113
UG37 12 147 203 78 48 2822 41 507 459
Carbopol 13 63 219 76 39 929 35 369 215
(Group 3) 14 130 245 77 55 1329 86 509 358
15 72 387 63 38 433 47 427 146
Group mean 97 225 71 46 1459 51 420 258
Median$ 66 94 61 39 554 44 386 275
#Numbers given are the sample dilutions at which relative luminescence units (RLU) were reduced by 50% compared to RLU in virus control wells after
subtraction of background RLU in cell control wells. All samples were taken two weeks after the third protein boost.
$Values above the median titer for each pseudovirus are shown in bold.
doi:10.1371/journal.pone.0114709.t002
Fig. 6. Cross-competition ELISA. Titration series of sera from two weeks after the third protein boost were
competed with biotinylated mAbs or biotinylated soluble domains 1–4 monomeric CD4 using UG37 gp140 as
the antigen and 50% inhibition titers (IT50) were calculated as the serum dilution at which binding of the
biotinylated probes was reduced by 50% compared to control well without serum. Epitopes targeted by the
mAbs are specified in parentheses. CD4bs: CD4 binding site; CD4i: CD4 inducible epitope. A one-way
ANOVA was performed for each competing protein/antibody with Dunnett’s post-hoc tests to compare Group
1 and Group 3 with the control Group 2. Significance is illustrated by **p,0.001.
doi:10.1371/journal.pone.0114709.g006
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against the V3-loop antibody HR10 and the gp41-targeting mAb 5F3, but not
against the V2-loop-directed mAb HGP68 (Fig. 6). Five macaques showed weak
competition against the CD4-induced (CD4i) epitopes of mAb 17b, indicating
some exposure of CD4i epitopes, which may have arisen from the binding of
gp140s to endogenous macaque CD4 on immunization. Additionally, competi-
tion was detected with 2G12, suggesting either the presence of glycan-specific
antibodies in the macaque sera or antibodies overlapping the 2G12 binding site
(Fig. 6).
Overall, the level of competition varied between macaques, although all
macaques generated antibodies that targeted multiple epitopes on gp140.
Additionally, targeting of the CD4bs was slightly improved in both HR and UC
macaques, compared to the UG37 RIBI control group.
Discussion
One of the major challenges for HIV-1 vaccine design is to tackle the enormous
genetic diversity of the virus by creating an immunogen that elicits bNAbs. It may
be necessary for a successful vaccine regimen to replicate the chronic exposure
experienced in natural infection during which somatic mutation of Env-specific
antibodies may lead to their increased neutralizing capacity [17, 58], potentially
resulting in NAbs of great potency and breadth [20, 26, 39]. Some polyvalent
vaccine regimens involving the co-administration of multiple monomeric gp120
[27, 29, 59] or gp140 [30] Env proteins generated improved NAb responses in
comparison to monovalent equivalents, as did the sequential administration of
different gp140 env DNA constructs [32]. Alternative approaches sought to focus
the B-cell response through the presentation of conserved Env regions or
consensus or founder sequences [60–63], with some success at inducing cross-
reactive NAbs. In the current study, we aimed to maximise the representation of
antigenic diversity of gp140 antigens through the generation of heterotrimers
from a diverse set of patient-derived Envs, and compared their immunogenicity to
homotrimeric UG37 gp140 in macaques. Our strategy incorporated three sources
of diversification: the use of 54 unique and genetically diverse envelopes; the
generation of gp140 heterotrimers to further increase the number of epitopes
displayed on the trimers, and the sequential rotation of heterotrimeric Env
deliveries of different subtypes around 6 anatomical sites on the macaques.
Sellhorn et al. described the generation of heterotrimers for which co-
transfection of two env expression constructs (subtype A and subtype B: SF162)
was performed in 239T cells [33]. The authors demonstrated the immunogenicity
of their heterotrimers in rabbits using a DNA-prime and protein-boost regimen,
and observed induction of antibodies with improved breadth of neutralization
with the heterotrimers than with homotrimeric (A/B-subtype) gp140. Here, we
adopted a similar approach to generate heterotrimers, but the proof-of-concept
sequential capture experiments extended to demonstrating the presence of three
different protomers from three different subtypes (A, B and C; A, D and F; B, C
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and F) within a given HIV-1 trimer. This builds on the work of Sellhorn and
colleagues, and establishes a principle whereby further increasing the diversity of a
polyvalent HIV-1 trimeric immunogen is possible. Many of the heterotrimers in
the mixes would have contained trimers in which each of the three polypeptides
composing the trimer was unique. The predicted result is that the polyvalent
heterotrimers could bind B-cells with cross-reactive BCRs more effectively than B-
cells specific to individual hypervariable regions. Indeed, individual protomers of
the heterotrimers with three distinct gp140s should trivalently bind better to B-
cells with cross-reactive BCRs specific to conserved epitopes between the three
trimer protomers, whilst BCRs with specificity to a single protomer or variable
region of the heterotrimer would have lower avidity to the antigen, resulting in
lower activation of these B-cell specificities. Six different mixes from env
constructs were formulated: four mixes contained envs from a single HIV-1
subtype (n59–15), Mix 5, which contained both D and F, and the final mix which
contained all 54 envs. By introducing the possibility of forming heterotrimers, the
polyvalency of a protein immunogen vastly increases: 10 different envs have the
potential to form up to 120 different Env trimer assemblies with a small
proportion of homotrimers, more heterotrimers with two different protomers,
and the majority being heterotrimers with three distinct Env protomers. Although
the extent of diversity present in the gp140 heterotrimer immunogens cannot be
precisely determined, the presence of many Envs within each immunogen mix was
demonstrated using mass spectrometry.
The macaque immunization study revealed a slightly improved neutralization
potency of elicited responses when using gp140 heterotrimer mixtures as
compared to a monovalent gp140 homotrimer, and also when carbopol 974P was
used as an adjuvant rather than RIBI. Levels of total gp140-specific antibodies in
the macaque sera, as determined by ELISA, were equivalent for the three groups
and were present at levels comparable to, or higher than, those elicited in other
immunization studies using gp120 or gp140 protein immunogens [30, 31, 64–66].
When using UG37 as the plating antigen, titers appeared to be lower in the HR
immunized macaques than in the other groups, but when the heterotrimeric
protein mixes were used for plating, titers in HR macaques were equivalent to
those seen in the UG37 gp140 ELISA for UR and UC. The NAb titers were similar
to those generated from previous gp140 immunizations for the easy-to-neutralize
viruses, such as SF162, MN.3 and MW965.26 [30, 31]. However, in contrast to
these previous macaque studies, our immunized macaques showed some
neutralization of tier 2 viruses. In other challenge studies, these levels of NAbs
were sufficient to provide protection against mucosal challenge [10, 13, 14], in
which protection correlated with NAb titers [13, 67].
In addition to generating good potency and breadth of NAb response, it is
desirable for a vaccine to induce antibodies that target the conserved regions of
the Env from which escape is less likely. For example, a number of bNAbs (e.g.,
VRC01) target the CD4bs [68–70] or glycosylated regions of the Env variable
loops (e.g., PG9, PGT122, PGT145) [19, 21, 71, 72], and patients with CD4bs Abs
are more likely to have broad and potent NAb responses [17, 73]. We used
Immunisation with Polyvalent vs Monovalent HIV-1 gp140
PLOS ONE | DOI:10.1371/journal.pone.0114709 December 9, 2014 22 / 29
competition ELISA to determine the specificity of the NAb responses in the three
macaque groups. All macaques generated NAbs specific to different epitopes
across the Env protein, but a marginally improved targeting of the CD4bs with
both the heterotrimeric gp140 RIBI or UG37-carbopol groups in comparison with
the homotrimeric UG37-RIBI was detected. Although SPR analyses demonstrated
comparable binding of soluble CD4 and a panel of mAbs between monomeric
UG37 gp140 and the most heterologous immunogen, Mix 6, these results fit with
the expectation that the presentation of different epitopes on the heterotrimers
results in multiple specificities of the NAbs. Indeed this is in line with observations
by Sellhorn et al., who reported alterations in exposure of epitopes at the CD4bs,
the co-receptor binding-site, and the MPER on their heterotrimers [33]. In the
adjuvant comparison study, the UG37 gp140 antigen was identical in the two
groups; however an increase in CD4bs titers was observed in the carbopol group.
The higher potency of NAb and increase in CD4bs-directed Abs generated by
carbopol could be attributed to an improved antigenic domination and specificity
of the adaptive immune response, and potentially due to its capacity to induce a
strong T-helper response and as an aqueous-based adjuvant that does not interfere
with the Env antigenic structure [34].
Despite the generation of high Env-specific IgG titers in the macaques after the
first and subsequent protein boosts, a significant decline in titers was observed
between protein administrations (up to 10-fold). A similar pattern was previously
observed in macaques immunized with Env trimers [66], where the authors also
analyzed the kinetics of the B-cell response to the immunogen. They observed a
significant increase in peripheral Env-specific antibody-secreting plasma cells
(PCs), which peaked 7 days after each protein immunization, but rapidly declined
to base levels. As in this study, Sundling and colleagues observed a rapid recall
response upon boosting which probably resulted from circulating memory B-cells
that differentiated into short-lived PCs [66]. They detected stable levels of
memory B-cells between immunizations, but levels would be expected to wane
over a longer period of time, as the Ab response against gp120 and gp140 Env is
not maintained long-term following clearance of the immunogen [74–76]. This
phenomenon is not restricted to the vaccination setting, as chronically-infected
HIV-1 individuals on ART with suppressed viral loads also experience a decline in
their plasma antibody and memory B-cell levels although slower than in the acute
phase [76]. Vaccines and infections of other diseases produce long-lived
neutralizing memory B-cells central to protection. It is therefore important to
understand the exact mechanisms involved in the generation of long-lived
memory responses.
In summary, we have demonstrated that it is possible to form heterotrimers
with three different Env protomers, both within and between HIV-1 subtypes, and
used this strategy to generate highly-diverse immunogens. Exposure of the
macaque immune system to these highly diverse gp140 heterotrimer immunogens
resulted in the generation of NAb responses of marginally improved breadth and
potency in comparison to monovalent homotrimeric gp140 using the same
adjuvant and improved targeting of antibodies to the CD4bs. Future studies will
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need to optimise the heterotrimeric regimen with new HIV-1 trimer and adjuvant
technologies that may enable more potent bNAb responses to be elicited. We also
demonstrate that carbopol is a safe and effective adjuvant for use in macaques and
capable of promoting an improved anti-HIV-1 NAb response compared to RIBI.
Further development of these vaccine strategies and testing in a challenge model
would be necessary to determine whether they could contribute towards HIV-1
protection.
Supporting Information
S1 Figure. Western blot analysis to detect specific capture and detection of Env
trimers with either one or two tags in series. Samples were separated by SDS-
PAGE and analysed separately by western blot with anti-His6, anti-FLAG and
anti-HA antibodies. Plasmids: 1 (His6), 2 (FLAG), 3 (HA), 4 (FLAG-His6) and 5
(HA-His6). (i) Rows 1–5: Supernatants following transient transfection with
plasmids 1–5; (ii) Rows 6–10: Elutions from Co2+ column (specific for His6)
following capture of supernatants 1–5; (iii) Rows 11–15: Elutions from anti-
FLAG-tagged magnetic beads following capture of supernatants 1–5.
doi:10.1371/journal.pone.0114709.s001 (TIF)
S2 Figure. Composite analysis of neutralization data. Tat-regulated Luc reporter
gene expression was determined to quantify reductions in virus infection in either
(A) TZM-bl or (B) A3R5 cells. Neutralization titers are the sample dilution at
which relative luminescence units (RLU) were reduced by 50% compared to RLU
in virus control wells after subtraction of background RLU in cell control wells.
Comparisons between groups were made individually using Mann Whitney tests.
Significance at p,0.05 is indicated.
doi:10.1371/journal.pone.0114709.s002 (TIF)
S3 Figure. TZM-bl neutralization ID50 titers in four macaques throughout the
protein immunization time-course. Macaque 2 (Group 1), Macaque 5 (Group
1), Macaque 9 (Group 2) and Macaque 13 (Group 3). (A) MN.3 (tier 1, subtype
B). (B) MW965.26 (tier 1, subtype C). In both, individual neutralization titers are
shown for each of the four macaques on the left-hand axis, and the mean gp140
ELISA titer of these four macaques is shown on the right-hand axis as serum
dilution factors (1/x).
doi:10.1371/journal.pone.0114709.s003 (TIF)
S1 Table. Primer details. Table of primers used for cDNA library formation from
purified viral RNA extracted from human serum and amplification of env genes
by RT-PCR and PCR for cloning into the expression vector pLEXm.
doi:10.1371/journal.pone.0114709.s004 (DOC)
S2 Table. Characterisation of gp140s by tandem mass spectrometry. Table of
Env peptides sequences derived from tandem mass spectrometry for either UG37
gp140 Env or heterotrimer Env samples.
doi:10.1371/journal.pone.0114709.s005 (DOC)
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S3 Table. ELISA titration end-points. Table of ELISA end point titers for
individual macaque sera at all experimental sampling timepoints.
doi:10.1371/journal.pone.0114709.s006 (DOCX)
Acknowledgments
We wish to acknowledge the Oxford University Biomedical Services Team for
their technical support. We thank Dr. Simon McGowan from the Computational
Biology Research Group for expert help with creating the database for the analysis
of mass spectrometry data. We thank Radu Ariescu at the Division of Structural
Biology, WTCHG, Oxford for providing the pLEXm protein expression vector.
Author Contributions
Conceived and designed the experiments: EJB TH AM GSJ. Performed the
experiments: EJB TS M. Rosario GAN JM CL GSJ. Analyzed the data: EJB TS GAN
JM BK CL AM DM QS TH GSJ. Contributed reagents/materials/analysis tools: M.
Ramaswamy QS TH. Wrote the paper: EJB TS BK TH GSJ.
References
1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination
with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209–2220.
2. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates
analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275–1286.
3. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the
HIV gp120 envelope glycoprotein. Nature 393: 705–711.
4. Walker LM, Burton DR (2010) Rational antibody-based HIV-1 vaccine design: current approaches and
future directions. Curr Opin Immunol 22: 358–366.
5. Yang X, Wyatt R, Sodroski J (2001) Improved elicitation of neutralizing antibodies against primary
human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75: 1165–
1171.
6. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, et al. (2006) Characterization of antibody responses
elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope
glycoproteins in selected adjuvants. J Virol 80: 1414–1426.
7. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, et al. (2007) A comparative immunogenicity
study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency
virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360: 329–340.
8. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al. (2000) Human neutralizing
monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency
virus infection. Nat Med 6: 200–206.
9. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly neutralizing
human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low
serum neutralizing titers. PLoS Pathog 5: e1000433.
10. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. (2009) Effective, low-titer
antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15: 951–
954.
Immunisation with Polyvalent vs Monovalent HIV-1 gp140
PLOS ONE | DOI:10.1371/journal.pone.0114709 December 9, 2014 25 / 29
11. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of Macaques
against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing
antibodies. J Virol 73: 4009–4018.
12. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody protects macaques
against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels
giving complete neutralization in vitro. J Virol 75: 8340–8347.
13. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, et al. (2008) Protection of macaques against
vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22:
339–348.
14. Bogers WM, Davis D, Baak I, Kan E, Hofman S, et al. (2008) Systemic neutralizing antibodies induced
by long interval mucosally primed systemically boosted immunization correlate with protection from
mucosal SHIV challenge. Virology 382: 217–225.
15. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, et al. (2007) Dissecting the
neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type
1-infected donors. J Virol 81: 6548–6562.
16. Doria-Rose NA, Klein RM, Manion MM, O’Dell S, Phogat A, et al. (2009) Frequency and phenotype of
human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing
antibodies. J Virol 83: 188–199.
17. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, et al. (2009) Factors associated with the
development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1
infection. J Virol 83: 757–769.
18. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. (2009) Human immunodeficiency virus type 1
elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-
throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337–7348.
19. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of memory B cell
responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected
individuals. PLoS One 5: e8805.
20. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage
of HIV by multiple highly potent antibodies. Nature 477: 466–470.
21. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing
antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289.
22. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, et al. (2011) A potent and broad neutralizing
antibody recognizes and penetrates the HIV glycan shield. Science 334: 1097–1103.
23. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/
V2 domain with broadly neutralizing antibody PG9. Nature 480: 336–343.
24. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, et al. (1994) Cross-neutralizing activity against
divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.
J Virol 68: 4031–4034.
25. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of
HIV-1 by a gp41-specific human antibody. Nature 491: 406–412.
26. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent
neutralization of HIV-1 by antibody VRC01. Science 329: 811–817.
27. Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, et al. (2001) Polyvalent envelope glycoprotein vaccine
elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against
heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 75: 2224–
2234.
28. Hurwitz JL, Slobod KS, Lockey TD, Wang S, Chou TH, et al. (2005) Application of the polyvalent
approach to HIV-1 vaccine development. Curr Drug Targets Infect Disord 5: 143–156.
29. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, et al. (2006) Polyvalent HIV-1 Env vaccine
formulations delivered by the DNA priming plus protein boosting approach are effective in generating
neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A,
B, C, D and E. Virology 350: 34–47.
Immunisation with Polyvalent vs Monovalent HIV-1 gp140
PLOS ONE | DOI:10.1371/journal.pone.0114709 December 9, 2014 26 / 29
30. Seaman MS, Leblanc DF, Grandpre LE, Bartman MT, Montefiori DC, et al. (2007) Standardized
assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1
envelope immunogens. Virology 367: 175–186.
31. Morner A, Douagi I, Forsell MN, Sundling C, Dosenovic P, et al. (2009) Human immunodeficiency
virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized
core protein. J Virol 83: 540–551.
32. Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, et al. (2011) Sequential
immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development
of neutralizing antibodies. J Virol 85: 5262–5274.
33. Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, et al. (2012) Engineering, expression,
purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.
J Virol 86: 128–142.
34. Krashias G, Simon AK, Wegmann F, Kok WL, Ho LP, et al. (2010) Potent adaptive immune responses
induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer. Vaccine 28: 2482–2489.
35. Dey AK, Burke B, Sun Y, Hartog K, Heeney JL, et al. (2012) Use of a polyanionic carbomer,
Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.
Vaccine 30: 2749–2759.
36. Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly DJ, et al. (2012) Mixed adjuvant formulations reveal
a new combination that elicit antibody response comparable to Freund’s adjuvants. PLoS One 7:
e35083.
37. Edo-Matas D, van Gils MJ, Bowles EJ, Navis M, Rachinger A, et al. (2010) Genetic composition of
replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC),
HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 405:
492–504.
38. Aricescu AR, Lu W, Jones EY (2006) A time- and cost-efficient system for high-level protein production
in mammalian cells. Acta Crystallogr D Biol Crystallogr 62: 1243–1250.
39. Jeffs SA, Goriup S, Kebble B, Crane D, Bolgiano B, et al. (2004) Expression and characterisation of
recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 22:
1032–1046.
40. Schmidt HA, Strimmer K, Vingron M, von Haeseler A (2002) TREE-PUZZLE: maximum likelihood
phylogenetic analysis using quartets and parallel computing. Bioinformatics 18: 502–504.
41. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, et al. (1995) Expression and
characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS
Res Hum Retroviruses 11: 533–539.
42. Davis SJ, Ward HA, Puklavec MJ, Willis AC, Williams AF, et al. (1990) High level expression in
Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation
variants. J Biol Chem 265: 10410–10418.
43. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, et al. (1994) Generation of human
monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for
peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10: 359–369.
44. Thali M, Moore JP, Furman C, Charles M, Ho DD, et al. (1993) Characterization of conserved human
immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol
67: 3978–3988.
45. Burton DR, Barbas CF 3rd, Persson MA, Koenig S, Chanock RM, et al. (1991) A large array of
human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of
asymptomatic seropositive individuals. Proc Natl Acad Sci U S A 88: 10134–10137.
46. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies
broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856–861.
47. Batycka M, Inglis NF, Cook K, Adam A, Fraser-Pitt D, et al. (2006) Ultra-fast tandem mass
spectrometry scanning combined with monolithic column liquid chromatography increases throughput in
proteomic analysis. Rapid Commun Mass Spectrom 20: 2074–2080.
Immunisation with Polyvalent vs Monovalent HIV-1 gp140
PLOS ONE | DOI:10.1371/journal.pone.0114709 December 9, 2014 27 / 29
48. Mackeen MM, Kramer HB, Chang KH, Coleman ML, Hopkinson RJ, et al. (2010) Small-molecule-
based inhibition of histone demethylation in cells assessed by quantitative mass spectrometry.
J Proteome Res 9: 4082–4092.
49. Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mvula A, Bridgeman A, et al. (2012) Prime-
boost regimens with adjuvanted synthetic long peptides elicit Tcells and antibodies to conserved regions
of HIV-1 in macaques. AIDS 26: 275–284.
50. Wegmann F, Krashias G, Luhn K, Laamanen K, Vieira S, et al. (2011) A novel strategy for inducing
enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. PLoS One 6:
e15861.
51. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type
1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited
neutralizing antibodies. J Virol 79: 10108–10125.
52. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of CCR5 and CD4 cell surface
concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.
J Virol 72: 2855–2864.
53. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human
immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob
Agents Chemother 46: 1896–1905.
54. Folks T, Benn S, Rabson A, Theodore T, Hoggan MD, et al. (1985) Characterization of a continuous T-
cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-
associated retrovirus. Proc Natl Acad Sci U S A 82: 4539–4543.
55. Kim JH, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola J, et al. (2003) Specific antibody
responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous
neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res Hum Retroviruses 19: 807–816.
56. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, et al. (2010) Replication competent molecular clones
of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:
1–13.
57. Muthumani K, Wise MC, Broderick KE, Hutnick N, Goodman J, et al. (2013) HIV-1 Env DNA vaccine
plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.
PLoS One 8: e84234.
58. Cole KS, Murphey-Corb M, Narayan O, Joag SV, Shaw GM, et al. (1998) Common themes of antibody
maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human
immunodeficiency virus type 1 infections. J Virol 72: 7852–7859.
59. Azizi A, Anderson DE, Ghorbani M, Gee K, Diaz-Mitoma F (2006) Immunogenicity of a polyvalent
HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters. BMC Immunol
7: 25.
60. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, et al. (2005) Antigenicity and immunogenicity of a synthetic
human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79: 1154–1163.
61. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, et al. (2006) Ancestral and consensus
envelope immunogens for HIV-1 subtype C. Virology 352: 438–449.
62. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, et al. (2007) Antigenicity and immunogenicity of
HIV-1 consensus subtype B envelope glycoproteins. Virology 360: 218–234.
63. Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, et al. (2006) A group M consensus
envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary
viruses. Virology 353: 268–282.
64. Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, et al. (2011) Antibody responses after
intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by
systemic priming or boosting with an adjuvanted formulation. Vaccine 29: 1421–1430.
65. Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, et al. (2010) Breadth of neutralizing
antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea
pigs. J Virol 84: 3270–3279.
66. Sundling C, Forsell MN, O’Dell S, Feng Y, Chakrabarti B, et al. (2010) Soluble HIV-1 Env trimers in
adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 207: 2003–2017.
Immunisation with Polyvalent vs Monovalent HIV-1 gp140
PLOS ONE | DOI:10.1371/journal.pone.0114709 December 9, 2014 28 / 29
67. Barnett SW, Burke B, Sun Y, Kan E, Legg H, et al. (2010) Antibody-mediated protection against
mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus
replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 84: 5975–
5985.
68. Pantophlet R, Wilson IA, Burton DR (2003) Hyperglycosylated mutants of human immunodeficiency
virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 77: 5889–5901.
69. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade
neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
J Virol 78: 13232–13252.
70. Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, et al. (2004) Identification and characterization of
a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
J Virol 78: 9233–9242.
71. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al. (2013) Crystal structure of a soluble cleaved
HIV-1 envelope trimer. Science 342: 1477–1483.
72. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, et al. (2013) A next-generation cleaved,
soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing
but not non-neutralizing antibodies. PLoS Pathog 9: e1003618.
73. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, et al. (2007) Broad HIV-1 neutralization mediated
by CD4-binding site antibodies. Nat Med 13: 1032–1034.
74. Anderson KP, Lucas C, Hanson CV, Londe HF, Izu A, et al. (1989) Effect of dose and immunization
schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J Infect Dis 160:
960–969.
75. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, et al. (1996) Safety and
immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A
randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 125: 270–279.
76. Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, et al. (2009) HIV-1 envelope induces
memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein
vaccination or HIV-1 infection. J Immunol 183: 2708–2717.
Immunisation with Polyvalent vs Monovalent HIV-1 gp140
PLOS ONE | DOI:10.1371/journal.pone.0114709 December 9, 2014 29 / 29
